Ricardo Martínez

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors

Amita Patnaik, Lee S. Rosen, Sara M. Tolaney et al. · Cancer Discovery · 2016 · 760 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer

Seth A. Wander, Ofir Cohen, Xueqian Gong et al. · Cancer Discovery · 2020 · 433 citations · Full text

Medicine, Cancer Biology, Oncology +17

A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer

Johanna C. Bendell, Anna M. Varghese, David M. Hyman et al. · Clinical Cancer Research · 2018 · 105 citations

Medicine, Oncology, Pharmacology +17

Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma

David S. Hong, Kathleen N. Moore, Manish R. Patel et al. · Clinical Cancer Research · 2018 · 88 citations · Full text

Medicine, Oncology, Pharmacology +17

Chemogenetic Evaluation of the Mitotic Kinesin CENP-E Reveals a Critical Role in Triple-Negative Breast Cancer

Pei‐Pei Kung, Ricardo Martínez, Zhou Zhu et al. · Molecular Cancer Therapeutics · 2014 · 69 citations

Life Sciences, Molecular Biology, Oncology +17